Efficacy of propranolol therapy after acute myocardial infarction related to coronary arterial anatomy and left ventricular function.
The effect of the beta-adrenergic blocking agent propranolol on morbidity and mortality risk after acute myocardial infarction was studied relative to coronary anatomy and left ventricular (LV) ejection fraction in a subset of 406 patients participating in a randomized study of 3,837 patients in the Beta Blocker Heart Attack Trial (BHAT). Median follow-up for this subset of patients was 28 months. The mortality rate was 2% (2 of 100) in patients with 2- and 3-vessel coronary artery disease taking propranolol and 10% (12 of 126) in those taking placebo (p less than 0.02). In patients with 2- and 3-vessel coronary artery disease with decreased LV function (defined as ejection fraction less than 50%), no patient taking propranolol died, whereas 17% (7 of 42) taking placebo died (p less than 0.04). The salutary effect of propranolol on mortality in the larger BHAT after acute myocardial infarction also was evident in this population studied in regard to their coronary and LV anatomy and function.
Jafri
S M
SM
Henry Ford Heart and Vascular Institute, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 48202.
Khaja
F
F
McFarland
T
T
Capone
R
R
Dahdah
S
S
Haywood
J
J
Edmiston
W A
WA
Tilley
B
B
Schultz
L
L
Goldstein
S
S
D003331:Coronary Vessels / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use*; D012307:Risk Factors; D013318:Stroke Volume
D011433:Propranolol